Methods
death, community-acquired pneumonia, pneumonia-related death
RECURRENT PNEUMONIA, SECONDARY, HYPERTENSION, SECONDARY INFECTION, COMMUNITY-ACQUIRED PNEUMONIA
This predefined secondary analysis investigated 180-day outcomes in 785 adult patients hospitalized with community-acquired pneumonia included in STEP, a randomised, placebo-controlled, double-blind trial. The primary endpoint was time to death from any cause at 180 days verified by telephone interview. Additional secondary endpoints included pneumonia-related death, readmission, recurrent pneumonia, secondary infections, new hypertension, and new insulin dependence.